Conditions: Breast Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 50
Healthy volunteers: no

Brief summary:
The purpose of this trial is to evaluate the efficacy, safety and pharmacokinetics of BIBW 2992, a dual, irreversible EGFR- and HER2-inhibitor, in two cohorts of patients with HER2-negative breast cancer after failure of no more than three regimen of prior chemotherapy.

Detailed description:

Arms:
arm 1: high dose once daily

Interventions: intervention 1: BIBW 2992
Intervention descriptions: intervention 1: high dose once daily

Protocol document: